Bacterial Pneumonia Clinical Trial
— Mini-LBAOfficial title:
Assessment of the Diagnostic Capacity of a New Sampling Technique for Lower Respiratory Tract Culture for Patients With Acute Infectious Pneumonia Admitted in Intensive Care Unit and Non Intubated.
Verified date | June 2011 |
Source | Assistance Publique - Hôpitaux de Paris |
Contact | n/a |
Is FDA regulated | No |
Health authority | France: Ministry of Health |
Study type | Interventional |
The aim of this study is to develop a safe and effective technique to take sample for lower respiratory tract cultures easy to perform in conditions of acute respiratory failure and spontaneous ventilation for patients admitted in intensive care unit for acute infectious pneumonia and non intubated. The investigators perform sample collection with a mini bronchoalveolar lavage catheter introduced by nasotracheal way through a suction catheter. The purpose of the study is to assess the microbiological diagnostic capacity of this new technique.
Status | Completed |
Enrollment | 36 |
Est. completion date | June 2011 |
Est. primary completion date | June 2011 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Age over 18 - Radiological diagnosis of pneumonia (community acquired or nosocomial) - No microbiological diagnosis known - Indication for culture of lower respiratory tract - Admission in intensive care unit required Exclusion Criteria: - Age lower than 18 - Bronchospasm - Coagulopathy ( Platelets count below 100 000/mm3, prothrombin time less than 50%, activated partial thromboplastin time ratio higher than 2) - Intubation with mechanical ventilation - Known microbiological diagnosis - Incapacity for consenting himself to the study |
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic
Country | Name | City | State |
---|---|---|---|
France | Dr Pascal MEYER | Corbeil | Ile de France |
Lead Sponsor | Collaborator |
---|---|
Assistance Publique - Hôpitaux de Paris | PLASTIMED Laboratory |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | The primary outcome measure is the rate of positive microbiological culture | one year | No | |
Secondary | Comparison between rate of positive culture obtain with mini bronchoalveolar lavage and the two others techniques used in the sudy: endotracheal aspiration and expectorated sputum | one year | No | |
Secondary | Feasibility of the procedure | ten minutes | No | |
Secondary | The acceptance of the procedure | ten minutes | Yes | |
Secondary | Physiological variables: heart and respiratory rate, oxygen saturation, blood pressure | before procedure and fifteen minutes after procedure | Yes | |
Secondary | If applicable: complications of the procedure | one day | Yes | |
Secondary | Time to obtain the result of the culture one day | one day | No | |
Secondary | Time of the procedure | one day | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT01570192 -
Clinical Trials to Reduce the Risk of Antimicrobial Resistance
|
Phase 2 | |
Recruiting |
NCT04952337 -
Clinical, Molecular and Functional Biomarkers for PROgnosis, Pathomechanisms and Treatment Strategies of COVID-19 (PROVID) - (PROVID-CAPNETZ)
|
||
Completed |
NCT02493764 -
Imipenem/Relebactam/Cilastatin Versus Piperacillin/Tazobactam for Treatment of Participants With Bacterial Pneumonia (MK-7655A-014)
|
Phase 3 | |
Completed |
NCT02531438 -
Omadacycline vs Moxifloxacin for the Treatment of CABP (EudraCT #2013-004071-13)
|
Phase 3 | |
Completed |
NCT00079885 -
Study Evaluating Tigecycline vs Levofloxacin in Hospitalized With Community-Acquired Pneumonia
|
Phase 3 | |
Recruiting |
NCT05629741 -
A 2-Part First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of CMTX-101
|
Phase 1 | |
Completed |
NCT05417997 -
Effect of Kunamin in SARS-CoV-2 RT-PCR Positive Covid-19 Patients
|
Phase 3 | |
Withdrawn |
NCT00645619 -
Use of TREM-1 Protein to Differentiate Viral and Bacterial Pneumonias in Intubated Children
|
||
Completed |
NCT00509106 -
Comparative Study of Ceftaroline vs. Ceftriaxone in Adults With Community-Acquired Pneumonia
|
Phase 3 | |
Completed |
NCT00080496 -
Study Evaluating Tigecycline Versus Imipenem/Cilastatin in Hospital-Acquired Pneumonia
|
Phase 3 | |
Completed |
NCT03158727 -
Cx611-0204 SEPCELL Study
|
Phase 1/Phase 2 | |
Completed |
NCT00621504 -
Comparative Study of Ceftaroline vs. Ceftriaxone in Adult Subjects With Community-Acquired Pneumonia
|
Phase 3 | |
Completed |
NCT00124020 -
Comparison of Telavancin and Vancomycin for Hospital-acquired Pneumonia Due to Methicillin-resistant Staphylococcus Aureus
|
Phase 3 | |
Completed |
NCT00081575 -
Study Comparing Tigecycline vs. Levofloxacin in Subjects Hospitalized With Community-Acquired Pneumonia
|
Phase 3 | |
Completed |
NCT00451386 -
Ertapenem Study in Pediatric Patients Who Have Urinary Tract Infections, Skin Infections or Community-acquired Pneumonia (0826-036)
|
Phase 2 | |
Recruiting |
NCT03752320 -
Multiplex Polymerase Chain Reaction in Postoperative Pneumonia After Thoracic Surgery
|
||
Active, not recruiting |
NCT04779242 -
Omadacycline vs. Moxifloxacin for the Treatment of Community-Acquired Bacterial Pneumonia
|
Phase 3 | |
Completed |
NCT00107952 -
Comparison of Telavancin and Vancomycin for Hospital-acquired Pneumonia Due to Methicillin-resistant Staphylococcus Aureus
|
Phase 3 | |
Terminated |
NCT03862040 -
Cefiderocol Concentrations in the Lungs of Hospitalized Patients With Bacterial Pneumonia
|
Phase 1 | |
Recruiting |
NCT05531149 -
Efficacy and Safety of Trimodulin (BT588) in Subjects With CAP Including COVID-19 Pneumonia
|
Phase 3 |